The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Press Release|Articles|December 3, 2024
Camber Pharmaceuticals Announces Addition of Decitabine for Injection
Listen
0:00 / 0:00
Key Takeaways
- Decitabine for Injection targets adult patients with myelodysplastic syndromes, including various subtypes and chronic myelomonocytic leukemia.
- The product is offered in a 50 mg single-dose vial, enhancing treatment accessibility.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Decitabine for Injection.
Decitabine for Injection is indicated for treatment of:
- adult patients with myelodysplastic syndromes (MDS)
- de novo and secondary MDS of all French-American British subtypes
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
Decitabine for Injection is available in a 50 mg Single-Dose Vial.
To find out more information on Decitabine for Injection please visit:
Advertisement
Related to this article
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
3
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
4
Pharmacists' Role as Ketone Monitoring Reaches Clinics
5